– Preclinical data show VIR-2482 has broad neutralizing potential against all major strains of influenza A from the last 100 years – – Extended half-life observed in Phase 1demonstrates potential for ...
Vir Biotechnology, Inc. VIR along with its partner GlaxoSmithKline GSK announced that they are expanding their COMET-ICE study to phase III. The study is evaluating their monoclonal antibody candidate ...
Both of these biotechs have promising COVID-19 programs. But one of them appears to have a clear edge. BioNTech and Pfizer are currently evaluating BNT162b2 in a pivotal late-stage clinical study. The ...
Preliminary, blinded pharmacokinetic and safety data from the first-in-human, randomized, placebo-controlled Phase 1 study, which demonstrate that intramuscular dosing of VIR-2482 was well tolerated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results